🔬 Current Disease Focus:
Task Progress: 0%
👥 Active Problem Solvers
0
🌍 Experts collaborating globally
⚡ Current Task Assignment
🧬 Genetic Analysis
🔄 Matching experts to specific tasks
📊 Resource Allocation by Research Phase:
📚 Data Analysis
🧪 Experimental Design
🔬 Clinical Trials
💊 Treatment Development
The purpose of this study is to determine if albiglutide is safe and effect...
Status
Completed
Location
GSK Investigational Site
Start Date
2009-02
Trial ID
NCT00838903
This study is designed to investigate the effect of treatment with albiglut...
Status
Completed
Location
Multiple Locations
Start Date
2011-07-06
Trial ID
NCT01406262
Treatments Being Tested
This is a randomized, double-blind, placebo-controlled, multicenter, 4-para...
Status
Completed
Location
GSK Investigational Site
Start Date
2010-04
Trial ID
NCT01098461
Treatments Being Tested
The incidence of Type 2 Diabetes Mellitus (T2DM) is increasing day by day b...
Status
Withdrawn
Location
GSK Investigational Site
Start Date
2017-08-14
Trial ID
NCT03015519
Treatments Being Tested
This study is designed to examine the efficacy and safety of 2 dose levels ...
Status
Completed
Location
GSK Investigational Site
Start Date
2013-02
Trial ID
NCT01733758
Treatments Being Tested
This randomized, double-blind, active-controlled study evaluates the effica...
Status
Completed
Location
GSK Investigational Site
Start Date
2010-05
Trial ID
NCT01098539
Treatments Being Tested
The drug effects will be studied after a single dose of 50 milligram (mg) a...
Status
Terminated
Location
GSK Investigational Site
Start Date
2016-09-20
Trial ID
NCT02802514
Treatments Being Tested
This is a phase III, randomized, double-blind, multicenter, parallel group,...
Status
Completed
Location
GSK Investigational Site
Start Date
2016-03-16
Trial ID
NCT02683746
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to trea...
Status
Completed
Location
GSK Investigational Site
Start Date
2015-07-01
Trial ID
NCT02465515
Treatments Being Tested
This is a Phase II, randomized, double-blind, parallel group, placebo contr...
Status
Completed
Location
GSK Investigational Site
Start Date
2014-10-10
Trial ID
NCT02284009
Treatments Being Tested